Changchun High-Tech
PulseAugur coverage of Changchun High-Tech — every cluster mentioning Changchun High-Tech across labs, papers, and developer communities, ranked by signal.
-
Shenyang Blower Works Group IPO approved; Moonshot AI raises $3.5B
Shenyang Blower Works Group has received approval from the China Securities Regulatory Commission to list on the Shanghai Stock Exchange's main board. In other news, a subsidiary of Changchun High-Tech, Jinsai Pharma, h…
-
GenSci144 drug for chronic kidney disease gains Chinese clinical trial approval
GenSci144, an oral small molecule inhibitor developed by Jinsai Pharmaceutical, has received approval for its clinical trial application in China. This drug targets the neutral amino acid transporter SLC6A19 and is inte…
-
Shenzhen offers smart product subsidies; AI to revolutionize drug development
Shenzhen is offering a 15% subsidy, capped at 1500 yuan, for purchases of smart home and other smart products in 2026. This initiative aims to encourage consumers to buy new, qualifying items. Separately, J.P. Morgan ho…
-
Changchun High-Tech subsidiary's drug gets FDA nod for US clinical trials
Changchun High-Tech's subsidiary, Gensci Pharmaceutical, has received approval from the U.S. FDA to commence clinical trials for its GenSci161 injection. This fully human bispecific antibody targets both IL-1α and IL-1β…